ISPOR-FDA Summit 2020 on Patient-Preference Information in Medical Devices Is Now Virtual

Published Jun 22, 2020

September 29 Summit Offers Complimentary Registration for All

ISPOR-FDA Summit 2020Lawrenceville, NJ, USA—June 22, 2020—ISPOR—the professional society for health economics and outcomes research, announced that its joint ISPOR-FDA Summit 2020 has been redesigned as a completely virtual event. The Summit, “Using Patient-Preference Information in Medical Device Regulatory Decisions: Benefit-Risk and Beyond,” is jointly sponsored by ISPOR and the US Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH). The virtual event will be held on September 29, 2020. Registration is being offered free of charge for all attendees.

Patient-preference information is increasingly being used in regulatory decision making for medical devices. Virtual ISPOR-FDA Summit 2020 will provide a forum to engage key stakeholders, including patient representatives, the medical device industry, researchers, payers and policymakers, healthcare providers, assessors, and regulators to discuss and explore the role, challenges, and opportunities of using patient-preference information across the healthcare ecosystem.

Summit speakers currently confirmed include: Michelle Tarver, MD, PhD, Center for Devices and Radiological Health, FDA; Anindita Saha, MS, Center for Devices and Radiological Health, FDA; David Gebben, PhD, Center for Devices and Radiological Health, FDA; Ryan Fischer, Parent Project Muscular Dystrophy; Suzanne Schrandt, JD, ExPPect, LLC; Juan Marcos Gonzalez, PhD, Duke University School of Medicine; Brett Hauber, PhD, RTI Health Solutions; Shelby Reed, RPh, PhD, Duke Clinical Research Institute; Ravishankar Jayadevappa, PhD, University of Pennsylvania Perelman School of Medicine; Dean Bruhn-Ding, RAC, CVRx, Inc; Dan Harfe, Tusker Medical, Inc; Bennett Levitan, MD, PhD, Janssen Research and Development; Barry R. Liden, Edwards Lifesciences; and Todd Snell, NxStage Medical of Fresenius Medical Care North America.

Registration for the Summit is complimentary. Prior registrants (for the previously scheduled event on March 31) do need to re-register for the new, completely virtual event now scheduled for September 29.

A pre-event webinar, “Patient-Preference Information—What It Is and What It Is Not,” is currently available on demand and provides a primer on the topic of patient-preference information. The webinar is recommended for Summit participants, is complimentary, and is available to be viewed by all (both registrants and non-registrants).

Additional information on Virtual ISPOR-FDA Summit 2020 can be found at:
Virtual ISPOR-FDA Summit 2020  |  Summit Program  |  Registration Information   |  Press

###

 

ABOUT ISPOR
ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field.
Website  | LinkedIn  | Twitter (@ispororg)  |  YouTube  |  Facebook  |  Instagram

Explore Related HEOR by Topic


Related Stories

ISPOR Tackles Health Disparities with New Research Primer

Jan 22, 2025

ISPOR announced today the publication of a report from the ISPOR Health Equity Research Special Interest Group intended to establish key concepts for conducting health equity research that enables investigators to examine—and ultimately reduce—unfair social inequities in health.

Global Expert Panel Releases Good Practices Guidance for Developing or Updating Health Technology Assessment Guidelines

Jan 14, 2025

ISPOR announced today the publication of a tripartite task force report outlining good practices for developing or updating health technology assessment (HTA) guidelines.

Rethinking Value Assessment for Orphan Drugs

Dec 18, 2024

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a special themed section of research papers that document challenges in rare disease evidence and economic evaluation and policy as well as ways in which the environment is evolving to address them.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×